SG10201607689PA - Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same - Google Patents

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same

Info

Publication number
SG10201607689PA
SG10201607689PA SG10201607689PA SG10201607689PA SG10201607689PA SG 10201607689P A SG10201607689P A SG 10201607689PA SG 10201607689P A SG10201607689P A SG 10201607689PA SG 10201607689P A SG10201607689P A SG 10201607689PA SG 10201607689P A SG10201607689P A SG 10201607689PA
Authority
SG
Singapore
Prior art keywords
generating
light chain
same
genetically modified
chain antibodies
Prior art date
Application number
SG10201607689PA
Other languages
English (en)
Inventor
John Mcwhirter
Lynn Macdonald
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201607689PA publication Critical patent/SG10201607689PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201607689PA 2012-03-16 2013-03-15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same SG10201607689PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611950P 2012-03-16 2012-03-16
US201261736930P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
SG10201607689PA true SG10201607689PA (en) 2016-10-28

Family

ID=48045078

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201607689PA SG10201607689PA (en) 2012-03-16 2013-03-15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
SG11201405165UA SG11201405165UA (en) 2012-03-16 2013-03-15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201405165UA SG11201405165UA (en) 2012-03-16 2013-03-15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same

Country Status (26)

Country Link
US (3) US9334334B2 (fr)
EP (4) EP3808175A1 (fr)
JP (5) JP6185978B2 (fr)
KR (1) KR102228296B1 (fr)
CN (3) CN107840890A (fr)
AU (3) AU2013204579B2 (fr)
BR (1) BR112014022850A2 (fr)
CA (1) CA2865643A1 (fr)
CY (2) CY1120599T1 (fr)
DK (2) DK2825036T3 (fr)
ES (3) ES2849349T3 (fr)
HK (2) HK1200273A1 (fr)
HR (2) HRP20180682T1 (fr)
HU (3) HUE037659T2 (fr)
IL (5) IL234355B (fr)
LT (3) LT3348140T (fr)
MX (1) MX355732B (fr)
MY (1) MY172730A (fr)
NZ (1) NZ629639A (fr)
PL (2) PL2825036T3 (fr)
PT (3) PT3348140T (fr)
RS (2) RS57118B1 (fr)
RU (2) RU2017135754A (fr)
SG (2) SG10201607689PA (fr)
SI (3) SI3348140T1 (fr)
WO (1) WO2013138680A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
CN107551270A (zh) 2008-04-11 2018-01-09 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
KR20230005405A (ko) 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
EP2762493B1 (fr) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
LT3216871T (lt) 2011-10-17 2022-03-25 Regeneron Pharmaceuticals, Inc. Pelės, turinčios apribotą imunoglobulino sunkiąją grandinę
RU2739792C1 (ru) 2011-11-30 2020-12-28 Чугаи Сейяку Кабусики Кайся Содержащий лекарственное средство переносчик в клетку для формирования иммунного комплекса
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
CA2865645A1 (fr) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Animaux non humains exprimant des sequences d'immunoglobuline sensibles au ph pour le batiment de l'antigene
EP2858487B1 (fr) 2012-06-12 2019-10-23 Regeneron Pharmaceuticals, Inc. Animaux non humains humanisés avec locus limités de chaîne lourde d'immunoglobuline
EP3597747B1 (fr) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Anticorps fc spécifiques fcgammarii de souris
KR20210084688A (ko) 2012-08-24 2021-07-07 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
HUE039214T2 (hu) 2013-02-20 2018-12-28 Regeneron Pharma Módosított szekvenciájú immunglobulin-nehézlánccal rendelkezõ, nem humán élõlények
WO2014163101A1 (fr) 2013-04-02 2014-10-09 中外製薬株式会社 Variant de région fc
SG11201508911PA (en) 2013-04-29 2015-11-27 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
MX2016008782A (es) 2014-01-15 2016-09-08 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US10183994B2 (en) 2014-06-30 2019-01-22 Merck Patent Gmbh Anti-TNFα antibodies with pH-dependent antigen binding for improved target clearence
TW201809008A (zh) * 2014-12-19 2018-03-16 日商中外製藥股份有限公司 抗ｃ５抗體及使用方法
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
EP3247723A1 (fr) * 2015-01-22 2017-11-29 Chugai Seiyaku Kabushiki Kaisha Combinaison de deux anticorps anti-c5 ou plus et ses procédés d'utilisation
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
EP3302553A4 (fr) * 2015-05-28 2019-03-06 Bio-rad Laboratories, Inc. Ligands d'affinité et procédés associés
RU2742606C2 (ru) * 2015-12-18 2021-02-09 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
SG10201707267RA (en) * 2015-12-18 2017-10-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
EP3457840B1 (fr) 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Procédés pour briser la tolérance immunologique à l'aide de multiples arn de guidage
WO2017210586A1 (fr) 2016-06-03 2017-12-07 Regeneron Pharmaceuticals, Inc. Animaux non humains exprimant la désoxynucléotidyltransférase terminale exogène
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
GB201707484D0 (en) * 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
BR112020018235A2 (pt) * 2018-03-14 2020-12-29 F. Hoffmann-La Roche Ag Métodos para gerar uma biblioteca de polinucleotídeos, bibliotecas de polinucleotídeos, uso de uma biblioteca, método para gerar uma biblioteca de anticorpos e método de seleção de um anticorpo
CN116514959A (zh) * 2018-03-24 2023-08-01 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類
PL3629720T3 (pl) 2018-06-14 2022-05-02 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek zdolne do rearanżacji dh-dh w sekwencjach kodujących łańcucha ciężkiego immunoglobuliny
JP6935383B2 (ja) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
CN113825614B (zh) 2019-04-04 2023-12-01 日精Asb机械株式会社 树脂容器的制造方法、注塑芯模具、注塑模具及树脂容器的制造设备
BR112021023683A2 (pt) 2019-06-05 2022-02-01 Regeneron Pharma Roedor e camundongo geneticamente modificado, embrião de roedor, célula b do roedor ou camundongo geneticamente modificado, hibridoma, população de células b, célula-tronco embrionária, célula de mamífero, métodos de produção de um anticorpo, de uma cadeia pesada, de um domínio variável, de uma coleção de domínios variáveis, de uma cadeia leve, de uma sequência nucleotídica, de um roedor geneticamente modificado e de células es, de geração de um domínio variável e in vitro para gerar uma célula recombinante de roedor, e, vetor de direcionamento
CN114761428A (zh) * 2019-10-28 2022-07-15 瑞泽恩制药公司 抗血凝素抗体及其使用方法
TW202221034A (zh) * 2020-08-04 2022-06-01 美商西根公司 抗ｃｄ２２８抗體和抗體－藥物共軛體
IL300975A (en) 2020-09-03 2023-04-01 Regeneron Pharma Methods for treating cancer pain by administering a PD-1 inhibitor
WO2022056276A1 (fr) 2020-09-11 2022-03-17 Regeneron Pharmaceuticals, Inc. Identification et production d'anticorps spécifiques à un antigène
US20240065239A1 (en) 2020-12-16 2024-02-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
EP4051700A1 (fr) 2020-12-23 2022-09-07 Regeneron Pharmaceuticals, Inc. Acides nucléiques codant pour des anticorps modifiés par ancrage et leurs utilisations

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991012023A2 (fr) 1990-02-16 1991-08-22 Boston Biomedical Research Institute Reactifs hybrides pouvant liberer des molecules de maniere selective dans des cellules
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) * 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5999908A (en) 1992-08-06 1999-12-07 Abelow; Daniel H. Customer-based product design module
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
ATE352613T1 (de) 1995-08-29 2007-02-15 Kirin Brewery Chimäres tier und methode zu dessen herstellung
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
AU750453B2 (en) 1997-10-03 2002-07-18 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
MXPA03002046A (es) 2000-09-08 2003-07-24 Massachusetts Inst Technology Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
CA2468565C (fr) 2001-11-30 2014-06-03 Abgenix, Inc. Animaux transgeniques porteurs de genes a chaine legere iglamba d'immunoglobuline humaine
CA2488836A1 (fr) 2002-06-12 2003-12-24 Genencor International, Inc. Methodes et compositions de liaison dependant du milieu d'un agent cible a une cible
DE60326839D1 (de) 2002-06-12 2009-05-07 Genencor Int Verfahren zur verbesserung einer bindungseigenschaft eines moleküls
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
EP1439234A1 (fr) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Transgénèse ciblée utilisant le locus 26
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (fr) 2003-05-30 2012-12-19 Merus B.V. Conception et utilisation de régions variables appariées de molécules de liaison spécifiques
EP1644417B1 (fr) 2003-07-15 2014-04-30 Therapeutic Human Polyclonals, Inc. Locus d'immunoglobuline humanises
CN1560081A (zh) 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
US7294754B2 (en) 2004-10-19 2007-11-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US7585504B2 (en) 2004-10-22 2009-09-08 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
AU2006242854A1 (en) 2005-04-29 2006-11-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Transgenic animals and methods of making recombinant antibodies
AU2006322445B2 (en) 2005-12-05 2011-05-12 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
EP2374818B1 (fr) 2006-06-02 2012-12-19 Regeneron Pharmaceuticals, Inc. Anticorps haute affinité du récepteur IL-6 humain
CA2664343C (fr) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. Anticorps humains a haute affinite vis-a-vis du recepteur il-4 humain
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CN101688228B (zh) 2007-03-13 2014-12-24 国家犾太健康中心 抗体产生的方法
ITMI20071522A1 (it) 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
EP3124497B1 (fr) 2007-09-14 2020-04-15 Adimab, LLC Bibliothèques d'anticorps synthétiques conçus de façon rationnelle et leurs utilisations
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
JP5591712B2 (ja) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
CN107551270A (zh) 2008-04-11 2018-01-09 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
MX2010011717A (es) * 2008-05-01 2010-11-30 Amgen Inc Anticuerpos anti-hepcidina y metodos de uso.
CA2729095C (fr) 2008-06-27 2018-12-04 Merus B.V. Methode de production d'un mammifere murin transgenique
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
DK2346994T3 (da) 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX2011007660A (es) 2008-12-18 2011-08-17 Kingdon Craig R Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
US8808136B2 (en) 2009-05-07 2014-08-19 Volvo Construction Equipment Ab Working machine and a method for operating a working machine
KR101805202B1 (ko) 2009-05-29 2017-12-07 모르포시스 아게 집합 및 집합의 사용 방법
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
WO2011158009A1 (fr) 2010-06-17 2011-12-22 Kymab Limited Modèles animaux et molécules thérapeutiques
DK2517557T4 (da) 2009-07-08 2023-09-25 Kymab Ltd Dyremodeller og terapeutiske molekyler
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US10106810B2 (en) 2009-07-16 2018-10-23 Wageningen Universiteit Regulation of zinc deficiency and tolerance in plants
GB2472108B (en) 2009-08-27 2011-07-13 Budha Singh Dhinjan Wall bead
ES2595376T3 (es) 2009-12-10 2016-12-29 Regeneron Pharmaceuticals, Inc. Ratones que producen anticuerpos de cadena pesada
HUE029785T2 (en) 2010-02-08 2017-04-28 Regeneron Pharma Common mouse light chain
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
KR20150002894A (ko) 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ｐＨ 의존성 항원 결합을 갖는 항체
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
BR112012033248A2 (pt) 2010-06-22 2017-11-28 Regeneron Pharma camundongos expressando uma cadeia leve com variável de lâmbda humana e regiões constantes de camundongo
DE14176593T1 (de) 2011-02-25 2015-03-05 Regeneron Pharmaceuticals, Inc. ADAM6 Mäuse
PL3572517T3 (pl) 2011-08-05 2021-10-04 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym uniwersalnym łańcuchem lekkim
MX366269B (es) 2011-09-30 2019-07-04 Chugai Pharmaceutical Co Ltd Biblioteca de moleculas de union dependientes de la concentracion ionica.
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
NZ630637A (en) 2012-03-06 2016-09-30 Regeneron Pharma Common light chain mouse
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
CA2865645A1 (fr) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Animaux non humains exprimant des sequences d'immunoglobuline sensibles au ph pour le batiment de l'antigene
MX2014014891A (es) 2012-06-05 2015-06-17 Regeneron Pharma Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun.
HUE039214T2 (hu) 2013-02-20 2018-12-28 Regeneron Pharma Módosított szekvenciájú immunglobulin-nehézlánccal rendelkezõ, nem humán élõlények

Also Published As

Publication number Publication date
EP3348140A3 (fr) 2018-10-03
CY1120491T1 (el) 2019-07-10
HRP20181228T1 (hr) 2018-10-05
BR112014022850A2 (pt) 2017-07-18
RS57414B1 (sr) 2018-09-28
CN104302169B (zh) 2017-11-17
HK1200273A1 (en) 2015-08-07
HUE039573T2 (hu) 2019-01-28
AU2016202323A1 (en) 2016-05-05
JP2019071910A (ja) 2019-05-16
US9422370B2 (en) 2016-08-23
JP2017104139A (ja) 2017-06-15
RU2017135754A3 (fr) 2021-01-27
IL272357B (en) 2021-05-31
HUE053310T2 (hu) 2021-06-28
PT3348140T (pt) 2021-01-07
US11192947B2 (en) 2021-12-07
AU2013204579B2 (en) 2016-01-14
MX355732B (es) 2018-04-27
EP2825036A1 (fr) 2015-01-21
JP6574802B2 (ja) 2019-09-11
EP2883449A1 (fr) 2015-06-17
WO2013138680A1 (fr) 2013-09-19
JP7199398B2 (ja) 2023-01-05
RU2014141537A (ru) 2016-05-20
US20130247234A1 (en) 2013-09-19
JP7304169B2 (ja) 2023-07-06
AU2018203713A1 (en) 2018-06-21
IL244097A0 (en) 2016-04-21
US20160311899A1 (en) 2016-10-27
CY1120599T1 (el) 2019-12-11
RU2644684C2 (ru) 2018-02-13
DK2825036T3 (en) 2018-07-16
HRP20180682T1 (hr) 2018-06-01
IL282452B (en) 2022-03-01
IL234355B (en) 2018-07-31
AU2013204579A1 (en) 2013-10-03
PL2883449T3 (pl) 2018-07-31
SI2825036T1 (en) 2018-08-31
WO2013138680A4 (fr) 2013-11-07
ES2665793T3 (es) 2018-04-27
PT2883449T (pt) 2018-05-07
LT2825036T (lt) 2018-07-10
SI2883449T1 (en) 2018-05-31
EP2825036B1 (fr) 2018-05-02
CN107840890A (zh) 2018-03-27
IL282452A (en) 2021-06-30
AU2016202323B2 (en) 2018-03-01
KR20140135193A (ko) 2014-11-25
CA2865643A1 (fr) 2013-09-19
DK2883449T3 (en) 2018-04-23
ES2679369T3 (es) 2018-08-24
SG11201405165UA (en) 2014-10-30
JP2022017547A (ja) 2022-01-25
IL244097A (en) 2017-06-29
JP2020108404A (ja) 2020-07-16
IL272357A (en) 2020-03-31
IL253775B (en) 2020-02-27
CN107827979A (zh) 2018-03-23
IL253775A0 (en) 2017-09-28
SI3348140T1 (sl) 2021-03-31
EP3348140B1 (fr) 2020-12-30
PL2825036T3 (pl) 2018-10-31
RU2017135754A (ru) 2019-02-08
JP6185978B2 (ja) 2017-08-23
KR102228296B1 (ko) 2021-03-17
LT3348140T (lt) 2021-01-25
LT2883449T (lt) 2018-05-10
NZ629639A (en) 2017-03-31
CN104302169A (zh) 2015-01-21
MX2014011051A (es) 2015-04-08
ES2849349T3 (es) 2021-08-17
US9334334B2 (en) 2016-05-10
HUE037659T2 (hu) 2018-09-28
EP3808175A1 (fr) 2021-04-21
RS57118B1 (sr) 2018-06-29
US20140329711A1 (en) 2014-11-06
MY172730A (en) 2019-12-11
EP2883449B1 (fr) 2018-02-07
EP3348140A2 (fr) 2018-07-18
PT2825036T (pt) 2018-07-26
HK1205642A1 (en) 2015-12-24
AU2018203713B2 (en) 2020-12-24
JP2015510767A (ja) 2015-04-13

Similar Documents

Publication Publication Date Title
IL282452B (en) Histidine-engineered light chain antibodies, and non-human animals genetically modified for their preparation
IL264358A (en) Histidine engineered light chain antibodies and non-human animals genetically engineered to produce them
EP2863736A4 (fr) Animaux génétiquement modifiés et procédés de production associés
EP2678434A4 (fr) Animaux génétiquement modifiés et procédés pour produire ceux-ci
GB201216564D0 (en) Genetically edited animal
DK2989893T3 (da) Ikke-humane dyr, der udtrykker antistoffer med fælles letkæde
HK1205145A1 (en) Improved antibody light chains
IL245306A0 (en) Preparations and methods for the production of genetically modified animals
EP2908625A4 (fr) Procédé de génération d'animaux génétiquement supérieurs